Denali Therapeutics (NASDAQ:DNLI) PT Lowered to $30.00

Denali Therapeutics (NASDAQ:DNLI) had its price objective cut by research analysts at Wedbush from $31.00 to $30.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Wedbush’s price target indicates a potential upside of 59.15% from the company’s current price. Wedbush also issued estimates for Denali Therapeutics’ FY2028 earnings at $1.74 EPS.

Several other equities analysts have also commented on DNLI. HC Wainwright reissued a “buy” rating and issued a $95.00 target price on shares of Denali Therapeutics in a report on Wednesday. UBS Group dropped their target price on Denali Therapeutics from $70.00 to $32.00 and set a “buy” rating on the stock in a report on Tuesday, April 9th. The Goldman Sachs Group dropped their target price on Denali Therapeutics from $73.00 to $50.00 and set a “buy” rating on the stock in a report on Thursday, February 29th. Finally, Stifel Nicolaus dropped their target price on Denali Therapeutics from $26.00 to $22.00 and set a “hold” rating on the stock in a report on Wednesday. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, Denali Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $40.22.

Denali Therapeutics Stock Up 1.0 %

NASDAQ:DNLI traded up $0.18 during trading hours on Wednesday, reaching $18.85. 43,017 shares of the stock were exchanged, compared to its average volume of 1,165,063. Denali Therapeutics has a twelve month low of $14.56 and a twelve month high of $33.31. The business has a 50-day moving average of $18.77 and a two-hundred day moving average of $18.84. The company has a market capitalization of $2.69 billion, a price-to-earnings ratio of -17.29 and a beta of 1.39.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings data on Tuesday, May 7th. The company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.01. Denali Therapeutics had a negative return on equity of 13.50% and a negative net margin of 36.51%. During the same quarter last year, the company earned ($0.80) EPS. On average, research analysts forecast that Denali Therapeutics will post -2.61 EPS for the current fiscal year.

Insider Transactions at Denali Therapeutics

In related news, Director Steve E. Krognes sold 2,750 shares of the firm’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $17.29, for a total value of $47,547.50. Following the completion of the sale, the director now owns 139,841 shares in the company, valued at $2,417,850.89. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, Director Vicki L. Sato sold 1,666 shares of the firm’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $18.37, for a total transaction of $30,604.42. Following the completion of the transaction, the director now directly owns 121,375 shares of the company’s stock, valued at approximately $2,229,658.75. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Steve E. Krognes sold 2,750 shares of the business’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $17.29, for a total value of $47,547.50. Following the completion of the transaction, the director now owns 139,841 shares of the company’s stock, valued at $2,417,850.89. The disclosure for this sale can be found here. Over the last quarter, insiders sold 110,955 shares of company stock worth $2,218,802. Company insiders own 7.90% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. CWM LLC grew its stake in shares of Denali Therapeutics by 216.7% during the 4th quarter. CWM LLC now owns 2,011 shares of the company’s stock valued at $43,000 after buying an additional 1,376 shares during the period. Assetmark Inc. grew its stake in shares of Denali Therapeutics by 49.1% during the 3rd quarter. Assetmark Inc. now owns 2,148 shares of the company’s stock valued at $44,000 after buying an additional 707 shares during the period. PNC Financial Services Group Inc. grew its stake in shares of Denali Therapeutics by 48.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 2,486 shares of the company’s stock valued at $53,000 after buying an additional 807 shares during the period. Fisher Asset Management LLC purchased a new stake in Denali Therapeutics during the 4th quarter worth $59,000. Finally, China Universal Asset Management Co. Ltd. boosted its position in Denali Therapeutics by 96.5% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,526 shares of the company’s stock worth $73,000 after purchasing an additional 1,732 shares during the period. 92.92% of the stock is currently owned by institutional investors and hedge funds.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.